When would you consider quantification of hepatitis B surface antigen as part of the treatment decision making process?  

It is not absolutely necessary. Treatment initiation decisions primarily hinge on expected benefit for reduction of inflammation, injury and fibrosis. qHBsAg is primarily a predictor of treatment duration, the likelihood of HBsAg loss during treatment.